Researchers have identified two new genes and implicated 25 distinct mutations in serious forms of epilepsy, suggesting a new direction for developing tailored treatments of the neurological disorders.
The findings by an international research collaboration, which includes study authors David Goldstein, PhD, director of the Duke Center for Human Genome Variation, and Erin Heinzen, PhD, assistant professor of medicine (Medical Genetics), appear Aug. 11 in the journal Nature.